Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults 18 Years and Older.
Essink, B; Sabharwal, C; Cannon, K; Frenck, R; Lal, H; Xu, X; Sundaraiyer, V; Peng, Y; Moyer, L; Pride, MW; et al.
Clinical Infectious Diseases.
2021.
Antibody in Lymphocyte Supernatant (ALS) responses after oral vaccination with live Shigella sonnei vaccine candidates WRSs2 and WRSs3 and correlation with serum antibodies, ASCs, fecal IgA and shedding.
Venkatesan, MM; Ballou, C; Barnoy, S; McNeal, M; El-Khorazaty, J; Frenck, R; Baqar, S.
PLoS ONE.
2021;
16.
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.
Zenilman, J; Belshe, R; Edwards, K; Self, S; Stanberry, L; Newell, T; Hunt, S; Jack, P; Adams, G; Ali-Abadi, N; et al.
New England Journal of Medicine.
2021;
385:1761-1773.
A site assessment tool for inpatient controlled human infection models for enteric disease pathogens.
Porter, CK; Detizio, KJ; Maier, N; Testa, KJ; Talaat, KR; Chen, WH; Lyon, CE; Gutierrez, RL; Frenck, R; Isidean, SD; et al.
Clinical Trials.
2021.
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.
Falsey, AR; Frenck, RW; Walsh, EE; Kitchin, N; Absalon, J; Gurtman, A; Lockhart, S; Bailey, R; Swanson, KA; Xu, X; et al.
New England Journal of Medicine.
2021;
385:1627-1629.
Heterologous SARS-CoV-2 Booster Vaccinations - Preliminary Report.
Atmar, RL; Lyke, KE; Deming, ME; Jackson, LA; Branche, AR; El Sahly, HM; Rostad, CA; Martin, JM; Johnston, C; Rupp, RE; et al.
2021.
BNT162b2 Covid-19 Vaccine in Adolescents. Reply.
Frenck, RW; Dormitzer, PR; Gurtman, A.
New England Journal of Medicine.
2021;
385.
Efficacy, safety, and immunogenicity of the Shigella sonnei 1790GAHB GMMA candidate vaccine: Results from a phase 2b randomized, placebo-controlled challenge study in adults.
Frenck, RW; Conti, V; Ferruzzi, P; Ndiaye, AG W; Parker, S; McNeal, MM; Dickey, M; Granada, JP; Cilio, GL; De Ryck, I; et al.
EClinicalMedicine.
2021;
39.
Shigella-Specific Immune Profiles Induced after Parenteral Immunization or Oral Challenge with Either Shigella flexneri 2a or Shigella sonnei.
Clarkson, KA; Talaat, KR; Frenck, RW; Alaimo, C; Martin, P; Bourgeois, AL; Kaminski, RW.
mSphere.
2021;
6.
Warp Speed for Coronavirus Disease 2019 (COVID-19) Vaccines: Why Are Children Stuck in Neutral?.
Anderson, EJ; Campbell, JD; Creech, CB; Frenck, R; Kamidani, S; Munoz, FM; Nachman, S; Spearman, P.
Clinical Infectious Diseases.
2021;
73:336-340.